Memantine prevents aluminum-induced cognitive deficit in rats

Behavioural Brain Research

Volumn 225, Issue 1, 2011, Pages 31-38

  Abdel Aal, Raafat A ^a   Assi, Abdel Azim A ^a   Kostandy, Botros B ^a  

^a ASSIUT UNIVERSITY   (Egypt)

Author keywords

Aluminum; Memantine; Memory; Neuroprotection

Indexed keywords

ALUMINUM CHLORIDE; MEMANTINE;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOPROPHYLAXIS; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; LOW DRUG DOSE; MALE; MAZE TEST; MORNING DOSAGE; NEUROPROTECTION; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RAT;

ALUMINUM; ANALYSIS OF VARIANCE; ANIMALS; BODY WEIGHT; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESCAPE REACTION; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; MALE; MAZE LEARNING; MEMANTINE; RATS; RATS, WISTAR; ROTAROD PERFORMANCE TEST; TIME FACTORS;

EID: 79960440188     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.06.031     Document Type: Article

References (72)

1. Bullock R. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date. Alzheimer Dis Assoc Disord 2006, 20:23-29.
2. Danysz W., Parsons C.G. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry 2003, 18:S23-S32.
3. Minkeviciene R., Banerjee P., Tanila H. Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2004, 311:677-682.
4. Van Dam D., De Deyn P.P. Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model. Eur Neuropsychopharmacol 2006, 16:59-69.
5. Miguel-Hidalgo J.J., Alvarez X.A., Cacabelos R., Quack G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid (1-40). Brain Res 2002, 958:210-221.
6. Yamada K., Takayanagi M., Kamei H., Nagai T., Dohniwa M., Kobayashi K., et al. Effects of memantine and donepezil on amyloid beta-induced memory impairment in a delayed-matching to position task in rats. Behav Brain Res 2005, 162:191-199.
7. Watanabe T., Iwasaki K., Takasaki K., Yamagata N., Fujino M., Nogami A., et al. Dynamin 1 depletion and memory deficits in rats treated with Abeta and cerebral ischemia. J Neurosci Res 2010, 88:1908-1917.
8. Kamat P.K., Tota S., Saxena G., Shukla R., Nath C. Okadaic acid (ICV) induced memory impairment in rats: a suitable experimental model to test anti-dementia activity. Brain Res 2010, 1309:66-74.
9. Misztal M., Frankiewicz T., Parsons C.G., Danysz W. Learning deficits induced by chronic intraventricular infusion of quinolinic acid-protection by MK-801 and memantine. Eur J Pharmacol 1996, 296:1-8.
10. Camarasa J., Rodrigo T., Pubill D., Escubedo E. Memantine is a useful drug to prevent the spatial and non-spatial memory deficits induced by methamphetamine in rats. Pharmacol Res 2010, 62:450-456.
11. Pietá Dias C., Martins de Lima M.N., Presti-Torres J., Dornelles A., Garcia V.A., Siciliani Scalco F., et al. Memantine reduces oxidative damage and enhances long-term recognition memory in aged rats. Neuroscience 2007, 146:1719-1725.
12. Heim C., Sontag K.H. Memantine prevents progressive functional neurodegeneration in rats. J Neural Transm Suppl 1995, 46:117-130.
13. Rosi S., Vazdarjanova A., Ramirez-Amaya V., Worley P.F., Barnes C.A., Wenk G.L. Memantine protects against LPS-induced neuroinflammation, restores behaviorally-induced gene expression and spatial learning in the rat. Neuroscience 2006, 142:1303-1315.
14. Andrási E., Páli N., Molnár Z., Kösel S. Brain aluminum, magnesium and phosphorus contents of control and Alzheimer-diseased patients. J Alzheimers Dis 2005, 7:273-284.
15. Wills M.R., Savory J. Water content of aluminum, dialysis dementia, and osteomalacia. Environ Health Perspect 1985, 63:141-147.
16. Xu N., Majidi V., Markesbery W.R., Ehmann W.D. Brain aluminum in Alzheimer's disease using an improved GFAAS method. Neurotoxicology 1992, 13:735-743.
17. Gauthier E., Fortier I., Courchesne F., Pepin P., Mortimer J., Gauvreau D. Aluminum forms in drinking water and risk of Alzheimer's disease. Environ Res 2000, 84:234-246.
18. Lukiw W.J. Alzheimer's disease and aluminium. Mineral and metal neurotoxicology 1997, 113-126. CRC Press, New York. M. Yasui, M.J. Strong, K. Ota, M.A. Verity (Eds.).
19. Schnabel J. Alzheimer's disease: arthritis of the brain?. New Sci 1992, 138:22-26.
20. Smith M.A., Sayre L.M., Monnier V.M., Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci 1995, 18:172-176.
21. Walton J.R. An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration. J Inorg Biochem 2007, 101:1275-1284.
22. Bilkei-Gorzó A. Neurotoxic effect of enteral aluminium. Food Chem Toxicol 1993, 31:357-361.
23. Gulya K., Rakonczay Z., Kása P. Cholinotoxic effects of aluminium in rat brain. J Neurochem 1990, 54:1020-1026.
24. Shuchang H., Qiao N., Piye N., Mingwei H., Xiaoshu S., Feng S., et al. Protective effects of gastrodia elata on aluminium-chloride-induced learning impairments and alterations of amino acid neurotransmitter release in adult rats. Restor Neurol Neurosci 2008, 26:467-473.
25. Abdel-Aal R.A., Assi A.A., Kostandy B.B. Rivastigmine reverses aluminum-induced behavioral changes in rats. Eur J Pharmacol 2011, 659:169-176.
26. Creeley C., Wozniak D.F., Labruyere J., Taylor G.T., Olney J.W. Low doses of memantine disrupt memory in adult rats. J Neurosci 2006, 26:3923-3932.
27. Van Dam D., Abramowski D., Staufenbiel M., De Deyn P.P. Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology 2005, 180:177-190.
28. Sukhanov I.M., Zakharova E.S., Danysz W., Bespalov A.Y. Effects of NMDA receptor channel blockers, MK-801 and memantine, on locomotor activity and tolerance to delay of reward in Wistar-Kyoto and spontaneously hypertensive rats. Behav Pharmacol 2004, 15:263-271.
29. Réus G.Z., Valvassori S.S., Machado R.A., Martins M.R., Gavioli E.C., Quevedo J. Acute treatment with low doses of memantine does not impair aversive, non-associative and recognition memory in rats. Naunyn Schmiedebergs Arch Pharmacol 2008, 376:295-300.
30. Pitsikas N., Sakellaridis N. Memantine and recognition memory: possible facilitation of its behavioral effects by the nitric oxide (NO) donor molsidomine. Eur J Pharmacol 2007, 571:174-179.
31. Yuedea C.M., Dong H., Csernansky J.G. Anti-dementia drugs and hippocampal-dependent memory in rodents. Behav Pharmacol 2007, 18:347-363.
32. Doody R.S., Tariot P.N., Pfeiffer E., Olin J.T., Graham S.M. Meta-analysis of six-month memantine trials in Alzheimer's disease. Alzheimers Dement 2007, 3:7-17.
33. Danysz W., Parsons C.G., Kornhuber J., Schmidt W.J., Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci Biobehav Rev 1997, 21:455-468.
34. Danysz W., Essmann U., Bresink I., Wilke R. Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol Biochem Behav 1994, 48:111-118.
35. Kos T., Popik P. A comparison of the predictive therapeutic and undesired side effects of the NMDA receptor antagonist, memantine, in mice. Behav Pharmacol 2005, 16:155-161.
36. Zajaczkowski W., Quack G., Danysz W. Infusion of (+)-MK-801 and memantine-contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur J Pharmacol 1996, 296:239-246.
37. Réus G.Z., Stringari R.B., Kirsch T.R., Fries G.R., Kapczinski F., Roesler R., et al. Neurochemical and behavioural effects of acute and chronic memantine administration in rats: further support for NMDA as a new pharmacological target for the treatment of depression?. Brain Res Bull 2010, 81:585-589.
38. Garibova T.L., Voronina T.A., Litvinova S.A., Kuznetsova A.L., Kul'chikov A.E., Alesenko A.V. Features of memantine action profile in cholinergic deficit and intracerebral posttraumatic hematoma (hemorrhagic stroke) models in rats. Eksp Klin Farmakol 2008, 71:8-13. [abstract].
39. Nakamura S., Murayama N., Noshita T., Katsuragi R., Ohno T. Cognitive dysfunction induced by sequential injection of amyloid-beta and ibotenate into the bilateral hippocampus; protection by memantine and MK-801. Eur J Pharmacol 2006, 548:115-122.
40. Kawahara M., Kato M., Kuroda Y. Effects of aluminum on the neurotoxicity of primary cultured neurons and on the aggregation of beta-amyloid protein. Brain Res Bull 2001, 55:211-217.
41. Niu Q., Yang Y., Zhang Q., Niu P., He S., Di Gioacchino M., et al. The relationship between Bcl-gene expression and learning and memory impairment in chronic aluminum-exposed rats. Neurotox Res 2007, 12:163-169.
42. Sun X., Liu Z., Zhang X., Zhang Z. Effects of aluminum on the number of neurons granulovacuolar degeneration in rats. Wei Sheng Yan Jiu 1999, 28:164-166. [abstract].
43. Connor D.J., Jope R.S., Harrell L.E. Chronic, oral aluminum administration to rats: cognition and cholinergic parameters. Pharmacol Biochem Behav 1988, 31:467-474.
44. Flaten T.P., Alfrey A.C., Birchall J.D., Savory J., Yokel R.A. Status and future concerns of clinical and environmental aluminum toxicology. J Toxicol Environ Health 1996, 48:527-541.
45. Schlatter C. Biomedical aspects of aluminium. Med Lav 1992, 83:470-474.
46. Julka D., Vasishta R.K., Gill K.D. Distribution of aluminum in different regions and body organs of rat. Biol Trace Elem Res 1996, 52:181-192.
47. Kaur A., Joshi K., Minz R.M., Gill K.D. Neurofilament phosphorylation and disruption: a possible mechanism of chronic aluminium toxicity in Wistar rats. Toxicology 2006, 219:1-10.
48. Lal B., Gupta A., Gupta A., Murthy R.C., Ali M.M., Chandra S.V. Aluminium ingestion alters behavior and some neurochemicals in rats. Indian J Exp Biol 1993, 31:30-35.
49. Sethi P., Jyoti A., Singh R., Hussain E., Sharma D. Aluminium-induced electrophysiological, biochemical and cognitive modifications in the hippocampus of aging rats. Neurotoxicology 2008, 29:1069-1079.
50. Platt B., Fiddler G., Riedel G., Henderson Z. Aluminium toxicity in the rat brain: histochemical and immunocytochemical evidence. Brain Res Bull 2001, 55:257-267.
51. Albrecht J., Simmons M., Dutton G.R., Norenberg M.D. Aluminum chloride stimulates the release of endogenous glutamate, taurine and adenosine from cultured rat cortical astrocytes. Neurosci Lett 1991, 127:105-107.
52. Mundy W.R., Freudenrich T.M., Kodavanti P.R. Aluminum potentiates glutamate-induced calcium accumulation and iron-induced oxygen free radical formation in primary neuronal cultures. Mol Chem Neuropathol 1997, 32:41-57.
53. Matyja E. Aluminum enhances glutamate-mediated neurotoxicity in organotypic cultures of rat hippocampus. Folia Neuropathol 2000, 38:47-53.
54. El-Rahman S.S. Neuropathology of aluminum toxicity in rats (glutamate and GABA impairment). Pharmacol Res 2003, 47:189-194.
55. Nayak P., Chatterjee A.K. Effects of aluminium exposure on brain glutamate and GABA systems: an experimental study in rats. Food Chem Toxicol 2001, 39:1285-1289.
56. Struys-Ponsar C., Guillard O., van den Bosch de Aguilar P. Effects of aluminum exposure on glutamate metabolism: a possible explanation for its toxicity. Exp Neurol 2000, 163:157-164.
57. Zielke H.R., Jackson M.J., Tildon J.T., Max S.R. A glutamatergic mechanism for aluminum toxicity in astrocytes. Mol Chem Neuropathol 1993, 19:219-233.
58. Brenner S.R., Yoon K.W. Aluminum toxicity in rat hippocampal neurons. Neurosci Lett 1994, 178:260-262.
59. Gilbert M.E., Shafer T.J. In vitro exposure to aluminum does not alter long-term potentiation or glutamate release in rat hippocampal slices. Neurotoxicol Teratol 1996, 18:175-180.
60. Provan S.D., Yokel R.A. Aluminum inhibits glutamate release from transverse rat hippocampal slices: role of G proteins, Ca channels and protein kinase C. Neurotoxicology 1992, 13:413-420.
61. Rosi S., Ramirez-Amaya V., Vazdarjanova A., Esparza E.E., Larkin P.B., Fike J.R., et al. Accuracy of hippocampal network activity is disrupted by neuroinflammation: rescue by memantine. Brain 2009, 132:2464-2477.
62. Wenk G.L., Zajaczkowski W., Danysz W. Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B. Behav Brain Res 1997, 83:129-133.
63. Nyakas C., Granic I., Halmy L.G., Banerjee P., Luiten P.G. The basal forebrain cholinergic system in ageing and dementia, rescuing cholinergic neurons from neurotoxic amyloid-beta42 with memantine. Behav Brain Res 2010, 221:594-603.
64. Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 2006, 5:160-170.
65. Lipton S.A. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets 2007, 8:621-632.
66. Wenk G.L., Parsons C.G., Danysz W. Potential role of N-methyl-d-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav Pharmacol 2006, 17:411-424.
67. Grotta J., Clark W., Coull B., Pettigrew L.C., Mackay B., Goldstein L.B., et al. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial. Stroke 1995, 26:602-605.
68. Herrling P.L. D-CPPene (SDZ EAA 494), a competitive NMDA antagonist: results from animal models and first results in humans. Neuropsychopharmacology 1994, 10:591S.
69. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994, 51:199-214.
70. Fix A.S., Horn J.W., Wightman K.A., Johnson C.A., Long G.G., Storts R.W., et al. Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex. Exp Neurol 1993, 123:204-215.
71. Olney J.W., Labruyere J., Wang G., Wozniak D.F., Price M.T., Sesma M.A. NMDA antagonist neurotoxicity: mechanism and prevention. Science 1991, 254:1515-1518.
72. Wozniak D.F., Dikranian K., Ishimaru M.J., Nardi A., Corso T.D., Tenkova T., et al. Disseminated corticolimbic neuronal degeneration induced in rat brain by MK-801: potential relevance to Alzheimer's disease. Neurobiol Dis 1998, 5:305-322.